Mitomycin C and capecitabine: An additional option as an advanced line therapy in patients with metastatic colorectal cancer

Table 4 Previous studies of mitomycin C/capecitabine as advanced line therapy in metastatic colorectal cancer

Ref.	Phase	Line of treatment	Number of patients (evaluable)	Study period (mo/yr)	Grade ≥ 3 AEs (%)	ORR (%)	DCR (%)	Median PFS (mo)	Median OS (mo)	1-yr OS (%)
Prospective studies
Chong et al[2], 2005	II	3	36 (33)	07/2001- 11/2003	NR1	15.2	63.7	5.4	9.3	30.6
Lim et al[19], 2005	II	3	21 (19)	03/2003- 03/2004	NR1	4.8	26.3	2.6	6.8	NR
Scartozzi et al[17], 2006	II	3	61	NR	NR1	8.0	48.0	3.0	6.0	NR
Retrospective studies
Chua et al[23], 2008	-	3	18 (14)	06/2003- 06/2007	16.7	0	11.0	2.7	5.4	NR
Saif et al22], 2013	-	4	15	07/2007- 02/2013	0	20.0	53.0	NA	NA	NR
Martorana et al[21], 2017	-	3	61	01/2008- 12/2014	9.0	5.0	29.5	3.3	9.3	NR
Current, 2023	-	≥ 3	119	03/2006- 11/2020	28.6	0.8	24.4	2.1	4.2	15.8

¹Studies reported the rates of each AE individually and did not report the total proportion of patients who experienced adverse events.

MMC: Mitomycin C; mCRC: Metastatic colorectal cancer; AE: Adverse event; ORR: Objective response rate; DCR: Disease control rate; PFS: Progression free survival; OS: Overall survival; NR: Not reported; NA: Not available.